|
시장보고서
상품코드
2076043
요로감염증 치료 시장 : 약제별, 적응증별, 지역별 - 시장 규모, 점유율, 전망 및 기회 분석(2025-2032년)Urinary Tract Infection Therapeutic Market, By Drug, By Indication, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032 |
||||||
요로감염증 치료 시장은 2026년에 97억 2,000만 달러 규모에 이를 것으로 추정되고 있어 2033년까지 122억 8,000만 달러에 이를 것으로 예상되고 있습니다. 2026년부터 2033년까지 CAGR 3.4%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 97억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간 CAGR : | 3.40% | 2033년 시장 규모 예측 : | 122억 8,000만 달러 |
요로감염증(UTI)이란 요로계의 어느 한 부위에서 발생하는 감염증을 말합니다. 여성은 남성에 비해 요로감염이 발생할 위험이 더 높습니다. 요로감염증(UTI)은 일반적으로 대변 속의 세균이 요로로 침입함으로써 발생합니다. 요로 감염의 초기 치료에는 일반적으로 항생제가 사용됩니다. 단순 요로감염증에 일반적으로 사용되는 약물로는 트리메토프림 및 설파메톡사졸(박트림, 박트림 DS), 포스포마이신(모노롤), 니트로플란토인(마크로단틴, 마크로비드, 플라단틴), 세파렉신, 세프토리악손 등이 있습니다.
시장 역학:
요로감염증의 높은 유병률, 당뇨병 및 신장결석 유병률 증가, 고령 인구 증가, 그리고 신규 치료 개발에 대한 관심 고조 등이 예측 기간 동안 전 세계 요로감염증 치료 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다.
2021년 10월, Spero Therapeutics Inc.는 감수성 미생물에 의한 신우신염을 포함한 복합성 요로감염증(cUTI) 치료로서 테비페넴 HBr 정제의 승인을 요청하는 신약승인신청서(NDA)를 미국 식품의약국(USFDA)에 제출했습니다. 또한, 2021년 9월에는 BDR Pharma사가 복강 내 감염증, 하기도 감염증 또는 합병증을 동반한 요로 감염증 환자를 대상으로 하는 치료로 비아페넴을 출시했습니다.
2020년 7월, 미국 식품의약국(FDA)은 성인의 복잡성 요로감염증(cUTI) 및 복잡성 복강 내 감염(cIAI) 치료인 항균제 ‘ 레카르브리오”(이미페넴, 실라스타틴, 레레박탐)을 승인했습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 요로감염증 치료 시장의 주요 기업 프로파일을 작성하고 있습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 세계 요로감염증 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 요로감염증 치료 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 요로감염증 치료 시장 : 약물별, 2021-2033년
제5장 세계의 요로감염증 치료 시장 : 적응증별, 2021-2033년
제6장 세계의 요로감염증 치료 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 애널리스트의 제안
제9장 섹션
JHS 26.07.09Urinary Tract Infection Therapeutic Market is estimated to be valued at USD 9.72 Bn in 2026 and is expected to reach USD 12.28 Bn by 2033, growing at a compound annual growth rate (CAGR) of 3.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 9.72 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.40% | 2033 Value Projection: | USD 12.28 Bn |
A urinary tract infection (UTI) is an infection in any part of the urinary system. Women are at greater risk of developing a urinary tract infection compared to men. Urinary tract infections (UTIs) are usually caused by bacteria from poo entering the urinary tract. Antibiotics usually are the first treatment for urinary tract infections. Medicines commonly used for simple UTI s include Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS), Fosfomycin (Monurol), Nitrofurantoin (Macrodantin, Macrobid, and Furadantin), Cephalexin, and Ceftriaxone.
Market Dynamics:
High prevalence of urinary tract infection, increasing prevalence of diabetes and kidney stones, increasing geriatric population, and increase in focus on the development of novel therapeutics are some major factors expected to drive growth of the global urinary tract infection therapeutic market during the forecast period.
In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Moreover, in September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.
In July 2020, the U.S. Food and Drug Administration (FDA) approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global urinary tract infection therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global urinary tract infection therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary tract infection therapeutic market.
Detailed Segmentation:
- Global Urinary Tract Infection Therapeutic Market By Drug (Revenue, USD Bn, 2021 - 2033)
- Penicillin and Combinations
- Quinolones
- Cephalosporin
- Azoles and Amphotericin B
- Nitrofurans
- Other Drugs
- Global Urinary Tract Infection Therapeutic Market By Indication; (Revenue, USD Bn, 2021 - 2033)
- Complicated UTI
- Uncomplicated UTI
- Other Indications
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Pfizer
- Novartis AG
- Cipla Inc.
- Bayer AG
- AstraZeneca
- Shionogi & Co. Ltd.
- GlaxoSmithKline PLC
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Urinary Tract Infection Therapeutic, By Drug
- Market Urinary Tract Infection Therapeutic, By Indication
- Market Urinary Tract Infection Therapeutic, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- High prevalence of urinary tract infection across the globe
- Adverse effects associated with the use of UTI medication
- Increase in focus on the development of novel drugs
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Urinary Tract Infection Therapeutic Market, By Drug, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Penicillin and Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Quinolones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Azoles and Amphotericin B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Nitrofurans
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Other Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Global Urinary Tract Infection Therapeutic Market, By Indication, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Complicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Uncomplicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
6. Global Urinary Tract Infection Therapeutic Market, By Geography, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
7. Competitive Landscape
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Shionogi & Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
8. Analyst Recommendation
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
9. Section
- References
- Research Methodology
- About Us and Sales Contact
